AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html. Biopharmaceutical, Biotechnology, Innovation, Research and Development, Manufacturing, Biotherapeutics, Oncology, Immunology, Virology, Neuroscience, Womens Health, Aesthetics, and Eye Care

Sectors: Pharmaceutical

Investing in the future Allianz X invests in innovative growth companies in ecosystems relevant to insurance and asset management. It has a global portfolio of around 25 companies and assets under management of about 1.7 billion euros. Allianz X has counted 12 unicorns among its portfolio so far. The heart, brains, and drive behind it all are a talented team of around 40 people in Munich and New York. On behalf of leading global insurer and asset manager Allianz Group, Allianz X provides an interface between Allianz companies and the broader ecosystem, enabling collaborative partnerships in insurtech, fintech, wealth, and …

Tags: DAX30 Sectors: Insurance

Seed Investor. We invest in People. Venture Capital for High-Tech Founders. Made in Germany. HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more …